Search results for "Mabs" in Articles / App Notes
Article
Innovative Chromatography Resins Can Improve Purity and Quality
Ongoing downstream challenges
Constraints still remain in downstream processing of mAbs, which continue to be the most successful segment of biological molecules in the market in terms of required…
Article
Single-Use for Downstream Chromatography: Benefit or Hindrance?
Single-use technology is gaining ground in downstream bioprocessing, but challenges stall further adoption.
By Feliza Mirasol
ARTMOIS/STOCK.ADOBE.COM
Biopharmaceutical manufactu…
Article
Challenges in Cell Harvesting Prompt Enhancements
al, “Recovery and Purification Process Development for Monoclonal Antibody Production,” MAbs online, DOI: 10.4161/mabs.2.5.12645, Sept. 1, 2010.
Article
Cost Considerations Drive Lean Technology in Biopharmaceutical Manufacturing
Monoclonal antibodies (mAbs) are the most common and most well-known class of biopharmaceuticals. As of February 2017, FDA lists 68 approved mAbs, and approvals have been increasing each year since th…
Article
Ligand-Binding Assays and the Determination of Biosimilarity
For monoclonal antibodies (mAbs), which make up a large portion of the biosimilars currently under development, it is important to remember that the different ends of the molecule are involved in bind…
Article
Single-Domain Antibodies for Brain Targeting
Going single domain
Biologic therapies such as monoclonal antibodies (mAbs) are enabling the targeted, personalized treatment of cancer, inflammatory diseases, infectious diseases, and diseases of…
Article
Digitalization: The Route to Biopharma 4.0
AI-ML Applications In Bioprocessing: ML as an Enabler of Real Time Quality Prediction in Continuous Manufacturing of Mabs. Computers & Chemical Engineering 2022, 164,107896. DOI: 10.1016/j.compchemeng…
Article
As the therapeutic pipeline diversifies, chromatography toolboxes are expanding.
For traditional mAbs, protein A chromatography is used to capture antibodies. Depending on the structure of the target antibody and the impurity profile, other affinities, like protein L or variants o…
Article
Top Process Development Trends for 2021 and a Look into 2022
…here has been a significant increase in titers of bioprocess, especially for monoclonal antibodies (mAbs). In the 1980s and 1990s, mAb titers were only 0.5 g/L. From the 1990s onward, the average mAb…
Article
Updating Viral Clearance for New Biologic Modalities
Guidance is needed
Compounding all these challenges is the fact that published regulatory guidances have been based on traditional biologics, such as mAbs and related Protein A binders, says Berri…